New data shows the drug is not more likely to cause birth defects.
March 12, 2020: The impact of age on viral suppression and immunologic recovery; chronic obstructive pulmonary disease risk among older PLWHIV; sex-based differences in older men vs. women; effect of aging on drug-drug interactions.
Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.
Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.
A lot of pregnancies in Botswana were anxiously followed after results from the Tsepamo study were revealed in late 2018. Updated data provide a medium-sized sigh of relief.
The findings will help providers manage patients who have known or potential resistance to NRTIs, but who we want to place on a simplified antiretroviral regimen.
The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.
The question of whether INSTIs cause weight gain continues to be debated. This story draws together some research on which drugs are associated with weight gain or other metabolic changes.
Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.
World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy
New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.